WO2000049134A1 - Proteines secretees et polynucleotides les codant - Google Patents

Proteines secretees et polynucleotides les codant Download PDF

Info

Publication number
WO2000049134A1
WO2000049134A1 PCT/US2000/004340 US0004340W WO0049134A1 WO 2000049134 A1 WO2000049134 A1 WO 2000049134A1 US 0004340 W US0004340 W US 0004340W WO 0049134 A1 WO0049134 A1 WO 0049134A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nucleotide sequence
nucleotide
amino acid
protein
Prior art date
Application number
PCT/US2000/004340
Other languages
English (en)
Other versions
WO2000049134A8 (fr
Inventor
Dario Valenzuela
Olive Yuan
Heidi Hoffman
Jeff Hall
Peter Rapiejko
Original Assignee
Alphagene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphagene, Inc. filed Critical Alphagene, Inc.
Priority to CA002362538A priority Critical patent/CA2362538A1/fr
Priority to AU28835/00A priority patent/AU2883500A/en
Priority to JP2000599860A priority patent/JP2002536973A/ja
Priority to EP00907313A priority patent/EP1153121A2/fr
Publication of WO2000049134A1 publication Critical patent/WO2000049134A1/fr
Publication of WO2000049134A8 publication Critical patent/WO2000049134A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • the present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
  • BACKGROUND OF THE INVENTION Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 1.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1 from nucleotide 737 to nucleotide 5302; the nucleotide sequence of SEQ ID NO: 1 from nucleotide 782 to nucleotide 5302; the nucleotide sequence of the full-length protein coding sequence of clone vb24_l deposited with the ATCC under accession number
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb24_l deposited with the ATCC under accession number
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ LD NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 756 to amino acid 765 of SEQ ID NO:2.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (ba) SEQ LD NO: 1 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:l; and (bb) the nucleotide sequence of the cDNA insert of clone vb24_l deposited with the ATCC under accession number 207113; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:l to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 1 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 1.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 1 from nucleotide 737 to nucleotide 5302, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:l from nucleotide 737 to nucleotide 5302, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:l from nucleotide 737 to nucleotide 5302.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: l from nucleotide 782 to nucleotide 5302, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:l from nucleotide 782 to nucleotide 5302, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 1 from nucleotide 782 to nucleotide 5302.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 756 to amino acid 765 of SEQ ID NO:2.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 60 to nucleotide 1130; the nucleotide sequence of SEQ ID NO:3 from nucleotide 156 to nucleotide 1130; the nucleotide sequence of the full-length protein coding sequence of clone vc64_l deposited with the ATCC under accession number 207113; or the nucleotide sequence of a mature protein coding sequence of clone vc64_l deposited with the ATCC under accession number 207113.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc64_l deposited with the ATCC under accession number 207113.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 173 to amino acid 182 of SEQ ID NO:4.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:3. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3 , but excluding the poly (A) tail at the 3' end of SEQ ID NO: 3.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 60 to nucleotide 1130, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 60 to nucleotide 1130, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 3 from nucleotide 60 to nucleotide 1130.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 156 to nucleotide 1130, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 156 to nucleotide 1130, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 156 to nucleotide 1130.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:4;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 195 to nucleotide 1298; the nucleotide sequence of SEQ ID NO:5 from nucleotide 333 to nucleotide 1298; the nucleotide sequence of the full-length protein coding sequence of clone vp20_l deposited with the ATCC under accession number
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp20_l deposited with the ATCC under accession number
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ ID NO: 6 having biological activity, the fragment comprising the amino acid sequence from amino acid 179 to amino acid 188 of SEQ ID NO:6.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and (bb) the nucleotide sequence of the cDNA insert of clone vp20_l deposited with the ATCC under accession number 207113; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 5 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:5.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 195 to nucleotide 1298, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 195 to nucleotide 1298, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 195 to nucleotide 1298.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 333 to nucleotide 1298, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 333 to nucleotide 1298, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 333 to nucleotide 1298.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 6 having biological activity, the fragment comprising the amino acid sequence from amino acid 179 to amino acid 188 of SEQ ID NO:6.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:7.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 129 to nucleotide 731; the nucleotide sequence of SEQ ID NO:7 from nucleotide 186 to nucleotide 731; the nucleotide sequence of the full-length protein coding sequence of clone vq4_l deposited with the ATCC under accession number 207113; or the nucleotide sequence of a mature protein coding sequence of clone vq4_l deposited with the ATCC under accession number 207113.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq4_l deposited with the ATCC under accession number 207113.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 95 to amino acid 104 of SEQ ID NO:8.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ DO NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:7.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 129 to nucleotide 731, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 129 to nucleotide 731, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 129 to nucleotide 731.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 186 to nucleotide 731, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 186 to nucleotide 731, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 186 to nucleotide 731.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:8;
  • the protein comprises the amino acid sequence of SEQ ID NO:8.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DO NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO: 10;
  • a polynucleotide which is an allelic variant of a polynucleotide of
  • such polynucleotide comprises the nucleotide sequence of SEQ DD NO:9 from nucleotide 143 to nucleotide 571; the nucleotide sequence of SEQ ID NO:9 from nucleotide 221 to nucleotide 571; the nucleotide sequence of the full-length protein coding sequence of clone vo7_l deposited with the ATCC under accession number PTA-362; or the nucleotide sequence of a mature protein coding sequence of clone vo7_l deposited with the ATCC under accession number PTA-362.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo7_l deposited with the ATCC under accession number PTA-362.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO: 10.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (ba) SEQ DD NO:9, but excluding the ⁇ oly(A) tail at the 3' end of SEQ ID NO:9; and (bb) the nucleotide sequence of the cDNA insert of clone vo7_l deposited with the ATCC under accession number PTA-362; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ DD NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:9.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 143 to nucleotide 571, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 143 to nucleotide 571, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 143 to nucleotide 571.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 221 to nucleotide 571, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 221 to nucleotide 571, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 221 to nucleotide 571.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO: 10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO: 10.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 11 from nucleotide 190 to nucleotide 570;
  • a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vc65_l deposited with the ATCC under accession number PTA-361;
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 11.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO: 11
  • nucleotide 112 to nucleotide 570 from nucleotide 112 to nucleotide 570; the nucleotide sequence of SEQ ID NO: 11 from nucleotide 190 to nucleotide 570; the nucleotide sequence of the full-length protein coding sequence of clone vc65_l deposited with the ATCC under accession number PTA- 361; or the nucleotide sequence of a mature protein coding sequence of clone vc65_l deposited with the ATCC under accession number PTA-361.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc65_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO: 12.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:l l.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vc65_l deposited with the ATCC under accession number PTA- 361; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 11 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:l l.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ DD NO: 11 from nucleotide 112 to nucleotide 570, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ DD NO: 11 from nucleotide 112 to nucleotide 570, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 11 from nucleotide 112 to nucleotide 570.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 11 from nucleotide 190 to nucleotide 570, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 11 from nucleotide 190 to nucleotide 570, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 11 from nucleotide 190 to nucleotide 570.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO: 12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO: 12.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc66_l deposited with the ATCC under accession number PTA-361;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 13 from nucleotide 4 to nucleotide 261; the nucleotide sequence of SEQ ID NO: 13 from nucleotide 124 to nucleotide 261; the nucleotide sequence of the full-length protein coding sequence of clone vc66_l deposited with the ATCC under accession number PTA- 361; or the nucleotide sequence of a mature protein coding sequence of clone vc66_l deposited with the ATCC under accession number PTA-361.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc66_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO: 14.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vc66_l deposited with the ATCC under accession number PTA- 361; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 13 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 13.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 13 from nucleotide 4 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:
  • nucleotide 124 to nucleotide 261 from nucleotide 124 to nucleotide 261, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 13 from nucleotide 124 to nucleotide 261, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 13 from nucleotide 124 to nucleotide 261.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO: 14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO: 14.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 15.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc68_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 160 to amino acid 169 of SEQ ID NO: 16.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO: 15. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vc68_l deposited with the ATCC under accession number PTA- 361; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 15 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 15.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ DD NO: 15 from nucleotide 135 to nucleotide 1227, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ DD NO: 15 from nucleotide 135 to nucleotide 1227, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 15 from nucleotide 135 to nucleotide 1227.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 15 from nucleotide 216 to nucleotide 1227, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 15 from nucleotide 216 to nucleotide 1227, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 15 from nucleotide 216 to nucleotide 1227.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 160 to amino acid 169 of SEQ ID NO: 16.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vk6_l deposited with the ATCC under accession number PTA-361;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 17 from nucleotide 79 to nucleotide 2424; the nucleotide sequence of SEQ ID NO: 17 from nucleotide 145 to nucleotide 2424; the nucleotide sequence of the full-length protein coding sequence of clone vk6_l deposited with the ATCC under accession number PTA- 361 ; or the nucleotide sequence of a mature protein coding sequence of clone vk6_l deposited with the ATCC under accession number PTA-361.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vk6_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment comprising the amino acid sequence from amino acid 386 to amino acid 395 of SEQ ID NO: 18.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (ba) SEQ DD NO: 17, but excluding the poly (A) tail at the 3' end of SEQ ID NO: 17; and (bb) the nucleotide sequence of the cDNA insert of clone vk6_l deposited with the ATCC under accession number PTA-361; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 17 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 17.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 17 from nucleotide 79 to nucleotide 2424, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ DD NO: 17 from nucleotide 79 to nucleotide 2424, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 17 from nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 17 from nucleotide 145 to nucleotide 2424, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 17 from nucleotide 145 to nucleotide 2424, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 17 from nucleotide 145 to nucleotide 2424.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment comprising the amino acid sequence from amino acid 386 to amino acid 395 of SEQ ID NO: 18.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO: 19.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO: 19.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo4_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:20.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO: 19. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO: 19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO: 19 , but excluding the poly(A) tail at the 3' end of SEQ ID NO: 19.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 19 from nucleotide 2 to nucleotide 733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 19 from nucleotide 2 to nucleotide 733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 19 from nucleotide 2 to nucleotide 733.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 19 from nucleotide 71 to nucleotide 733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 19 from nucleotide 71 to nucleotide 733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 19 from nucleotide 71 to nucleotide 733.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:20;
  • the protein comprises the amino acid sequence of SEQ ID NO:20.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 151 to nucleotide 1323; the nucleotide sequence of SEQ DD NO:21 from nucleotide 217 to nucleotide 1323; the nucleotide sequence of the full-length protein coding sequence of clone vo8_l deposited with the ATCC under accession number PTA- 361; or the nucleotide sequence of a mature protein coding sequence of clone vo8_l deposited with the ATCC under accession number PTA-361.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo8_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID NO:22.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (ba) SEQ DO NO:21 , but excluding the ⁇ oly(A) tail at the 3' end of SEQ ID NO:21; and (bb) the nucleotide sequence of the cDNA insert of clone vo8_l deposited with the ATCC under accession number PTA-361 ; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:21 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:21.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 151 to nucleotide 1323, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ DD NO:21 from nucleotide 151 to nucleotide 1323, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 217 to nucleotide 1323, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 217 to nucleotide 1323, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 217 to nucleotide 1323.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 22 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID NO:22.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:23.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:23
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol0_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 75 to amino acid 84 of SEQ ID NO:24.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:23. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vol0_l deposited with the ATCC under accession number PTA- 361; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:23 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:23.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ DD NO:23 from nucleotide 134 to nucleotide 613, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ DD NO:23 from nucleotide 134 to nucleotide 613, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 134 to nucleotide 613.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 215 to nucleotide 613, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 215 to nucleotide 613, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 215 to nucleotide 613.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 75 to amino acid 84 of SEQ ID NO:24.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vo20_l deposited with the ATCC under accession number PTA-361;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 102 to nucleotide 1163; the nucleotide sequence of SEQ DD NO:25 from nucleotide 156 to nucleotide 1163; the nucleotide sequence of the full-length protein coding sequence of clone vo20_l deposited with the ATCC under accession number PTA- 361; or the nucleotide sequence of a mature protein coding sequence of clone vo20_l deposited with the ATCC under accession number PTA-361.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo20_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 172 to amino acid 181 of SEQ ID NO:26.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vo20_l deposited with the ATCC under accession number PTA- 361; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:25 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:25.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ DD NO:25 from nucleotide 102 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:
  • nucleotide 156 to nucleotide 1163 from nucleotide 156 to nucleotide 1163, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 156 to nucleotide 1163, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 156 to nucleotide 1163.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 172 to amino acid 181 of SEQ ID NO:26.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:27.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo21_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:28.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:27. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vo21_l deposited with the ATCC under accession number PTA- 361; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:27 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:27.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 27 from nucleotide 67 to nucleotide 702, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 67 to nucleotide 702, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 67 to nucleotide 702.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 27 from nucleotide 157 to nucleotide 702, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 27 from nucleotide 157 to nucleotide 702, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 157 to nucleotide 702.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 28 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:28.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp24_l deposited with the ATCC under accession number PTA-361;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 57 to nucleotide 272; the nucleotide sequence of SEQ ID NO:29 from nucleotide 114 to nucleotide 272; the nucleotide sequence of the full-length protein coding sequence of clone vp24_l deposited with the ATCC under accession number PTA- 361; or the nucleotide sequence of a mature protein coding sequence of clone vp24_l deposited with the ATCC under accession number PTA-361.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp24_l deposited with the ATCC under accession number PTA- 361.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 31 to amino acid 40 of SEQ ID NO: 30.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vp24_l deposited with the ATCC under accession number PTA- 361; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:29.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 29 from nucleotide 57 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:
  • nucleotide 114 to nucleotide 272 from nucleotide 114 to nucleotide 272, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 114 to nucleotide 272, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 114 to nucleotide 272.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 30 having biological activity, the fragment comprising the amino acid sequence from amino acid 31 to amino acid 40 of SEQ ID NO:30.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:31.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:31
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vol7_l deposited with the ATCC under accession number PTA- 366.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:32.
  • inventions provide the gene conesponding to the cDNA sequence of SEQ ID NO:31.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vol7_l deposited with the ATCC under accession number PTA- 366; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:31 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:31 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:31.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 757, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 757, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO: 31 from nucleotide 38 to nucleotide 757.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 137 to nucleotide 757, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 137 to nucleotide 757, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 137 to nucleotide 757.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:32.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql 1_1 deposited with the ATCC under accession number PTA-367;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:33 from nucleotide 93 to nucleotide 263; the nucleotide sequence of SEQ ID NO:33 from nucleotide 174 to nucleotide 263; the nucleotide sequence of the full-length protein coding sequence of clone vql 1_1 deposited with the ATCC under accession number PTA- 367; or the nucleotide sequence of a mature protein coding sequence of clone vql l_l deposited with the ATCC under accession number PTA-367.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql 1_1 deposited with the ATCC under accession number PTA- 367.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 34 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO:34.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vql l_l deposited with the ATCC under accession number PTA- 367; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:33, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:33 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 33 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:33.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 93 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:
  • nucleotide 174 to nucleotide 263 from nucleotide 174 to nucleotide 263, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 174 to nucleotide 263, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 174 to nucleotide 263.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:34, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO:34.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:35.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:35
  • nucleotide sequence of SEQ ID NO:35 from nucleotide 85 to nucleotide 1125; the nucleotide sequence of the full-length protein coding sequence of clone vql2_l deposited with the ATCC under accession number PTA- 367; or the nucleotide sequence of a mature protein coding sequence of clone vql2_l deposited with the ATCC under accession number PTA-367.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql2_l deposited with the ATCC under accession number PTA- 367.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 175 to amino acid 184 of SEQ ID NO:36.
  • inventions provide the gene conesponding to the cDNA sequence of SEQ ID NO:35. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vql2_l deposited with the ATCC under accession number PTA- 367; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 35, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:35 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:35 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:35.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 35 from nucleotide 43 to nucleotide 1125, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 43 to nucleotide 1125, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 43 to nucleotide 1125.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 85 to nucleotide 1125, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 85 to nucleotide 1125, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 85 to nucleotide 1125.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 175 to amino acid 184 of SEQ ID NO:36.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql4_l deposited with the ATCC under accession number PTA-367;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:37 from nucleotide 32 to nucleotide 904; the nucleotide sequence of SEQ ID NO:37 from nucleotide 77 to nucleotide 904; the nucleotide sequence of the full-length protein coding sequence of clone vql4_l deposited with the ATCC under accession number PTA- 367; or the nucleotide sequence of a mature protein coding sequence of clone vql4_l deposited with the ATCC under accession number PTA-367.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql4_l deposited with the ATCC under accession number PTA- 367.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 140 to amino acid 149 of SEQ ID NO:38.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vql4_l deposited with the ATCC under accession number PTA- 367; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:37 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:37 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:37.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 32 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:
  • nucleotide 77 to nucleotide 904 from nucleotide 77 to nucleotide 904, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 77 to nucleotide 904, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 77 to nucleotide 904.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:38, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 140 to amino acid 149 of SEQ ID NO:38.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vql5_l deposited with the ATCC under accession number PTA-367;
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql5_l deposited with the ATCC under accession number PTA-367;
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:39.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:39.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql5_l deposited with the ATCC under accession number PTA- 367.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 130 to amino acid 139 of SEQ ID NO:40.
  • inventions provide the gene conesponding to the cDNA sequence of SEQ ID NO:39. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vql5_l deposited with the ATCC under accession number PTA- 367; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:39 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:39 , but excluding the ⁇ oly(A) tail at the 3' end of SEQ ID NO:39.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ DD NO:39 from nucleotide 384 to nucleotide 1 193, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ DD NO:39 from nucleotide 384 to nucleotide 1193, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 384 to nucleotide 1193.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 642 to nucleotide 1193, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 642 to nucleotide 1193, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 642 to nucleotide 1193.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 130 to amino acid 139 of SEQ ID NO:40.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql7_l deposited with the ATCC under accession number PTA-367;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 132 to nucleotide 503; the nucleotide sequence of SEQ DD NO:41 from nucleotide 189 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone vql7_l deposited with the ATCC under accession number PTA- 367; or the nucleotide sequence of a mature protein coding sequence of clone vql7_l deposited with the ATCC under accession number PTA-367.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql7_l deposited with the ATCC under accession number PTA- 367.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 57 to amino acid 66 of SEQ ID NO:42.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vql7_l deposited with the ATCC under accession number PTA- 367; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:41 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:41 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:41.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ DD NO:41 from nucleotide 132 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:41
  • nucleotide 189 to nucleotide 503 from nucleotide 189 to nucleotide 503, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 189 to nucleotide 503, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 189 to nucleotide 503.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 57 to amino acid 66 of SEQ ID NO:42.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone vql8_l deposited with the ATCC under accession number PTA-367;
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vql8_l deposited with the ATCC under accession number PTA-367;
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:43.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:43
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vql8_l deposited with the ATCC under accession number PTA- 367.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID NO:44.
  • inventions provide the gene conesponding to the cDNA sequence of SEQ ID NO:43. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vql8_l deposited with the ATCC under accession number PTA- 367; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:43 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:43.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 69 to nucleotide 401, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 69 to nucleotide 401, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 69 to nucleotide 401.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 138 to nucleotide 401, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 138 to nucleotide 401, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 138 to nucleotide 401.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:44, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID NO:44.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq22_l deposited with the ATCC under accession number PTA-367;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 65 to nucleotide 1180; the nucleotide sequence of SEQ ID NO:45 from nucleotide 149 to nucleotide 1180; the nucleotide sequence of the full-length protein coding sequence of clone vq22_l deposited with the ATCC under accession number PTA- 367; or the nucleotide sequence of a mature protein coding sequence of clone vq22_l deposited with the ATCC under accession number PTA-367.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq22_l deposited with the ATCC under accession number PTA- 367.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:46.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vq22_l deposited with the ATCC under accession number PTA- 367; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:45 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:45 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:45.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 65 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:45
  • nucleotide 149 to nucleotide 1180 from nucleotide 149 to nucleotide 1180, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 149 to nucleotide 1180, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 149 to nucleotide 1180.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:46.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:47.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:47.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vr3_l deposited with the ATCC under accession number PTA- 367.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 227 to amino acid 236 of SEQ ID NO:48.
  • inventions provide the gene conesponding to the cDNA sequence of SEQ ID NO:47.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:47 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:47.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 18 to nucleotide 1409, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ DD NO:47 from nucleotide 18 to nucleotide 1409, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 18 to nucleotide 1409.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 60 to nucleotide 1409, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 60 to nucleotide 1409, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 60 to nucleotide 1409.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:48;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb26_l deposited with the ATCC under accession number PTA-501;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 690 to nucleotide 2570; the nucleotide sequence of SEQ ID NO:49 from nucleotide 765 to nucleotide 2570; the nucleotide sequence of SEQ ID NO:49 from nucleotide 1286 to nucleotide 2895; the nucleotide sequence of SEQ ID NO:49 from nucleotide 1286 to nucleotide 2570; the nucleotide sequence of SEQ ID NO:49 from nucleotide 981 to nucleotide 1282; the nucleotide sequence of the full-length protein coding sequence of clone vb26_l deposited with the ATCC under accession number PTA-501 ; or the nucleotide sequence of a mature protein coding sequence of clone vb26_l deposited with the ATCC under accession number PTA-501.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb26_l deposited with the ATCC under accession number PTA-501.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ DO NO: 50 from amino acid 112 to amino acid 197.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ DD NO:50 having biological activity, the fragment comprising an amino acid sequence selected from the group comprising the sequence from amino acid 308 to amino acid 317 of SEQ ID NO:50, the sequence from amino acid 112 to amino acid 197 of SEQ ID NO:50, the sequence from amino acid 200 to amino acid 627 of SEQ ID NO:50, and the sequence from amino acid 364 to amino acid 373 of SEQ ID NO:50.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:49, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:49 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:49 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:49.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ DD NO:49 from nucleotide 690 to nucleotide 2570, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ DO NO:49 from nucleotide 690 to nucleotide 2570, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ DD NO:49 from nucleotide 690 to nucleotide 2570.
  • the polynucleotide isolated according to the above process comprises a nucjeotide sequence conesponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 765 to nucleotide 2570, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 765 to nucleotide 2570, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ DD NO:49 from nucleotide 765 to nucleotide 2570.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 1286 to nucleotide 2895, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 1286 to nucleotide 2895, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 1286 to nucleotide 2895.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:50;
  • a fragment of the amino acid sequence of SEQ ID NO:50 (c) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and (d) the amino acid sequence encoded by the cDNA insert of clone vb26_l deposited with the ATCC under accession number PTA-501; the protein being substantially free from other mammalian proteins.
  • such protein comprises the amino acid sequence of SEQ ID NO:50 or the amino acid sequence of SEQ ID NO:50 from amino acid 112 to amino acid 197.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 50 having biological activity, the fragment comprising an amino acid sequence selected from the group comprising the sequence from amino acid 308 to amino acid 317 of SEQ ID NO:50, the sequence from amino acid 112 to amino acid 197 of SEQ ID NO:50, the sequence from amino acid 200 to amino acid 627 of SEQ ID NO:50, and the sequence from amino acid 364 to amino acid 373 of SEQ ID NO:50.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:51.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:51.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc70_l deposited with the ATCC under accession number PTA- 1074.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 265 to amino acid 274 of SEQ ID NO:52.
  • Other embodiments provide the gene conesponding to the cDNA sequence of SEQ
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of: (aa) SEQ DD NO: 51 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and
  • step (bb) the nucleotide sequence of the cDNA insert of clone vc70_l deposited with the ATCC under accession number PTA- 1074; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:51 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:51 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:51.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ DD NO: 51 from nucleotide 105 to nucleotide
  • nucleotide 1724 and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 105 to nucleotide 1724, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 105 to nucleotide 1724.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 186 to nucleotide 1724, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 186 to nucleotide 1724, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 186 to nucleotide 1724.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:52, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 52 having biological activity, the fragment comprising the amino acid sequence from amino acid 265 to amino acid 274 of SEQ ID NO:52.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:53.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53 from nucleotide 3 to nucleotide 239; the nucleotide sequence of the full-length protein coding sequence of clone vo28_l deposited with the ATCC under accession number PTA-1074; or the nucleotide sequence of a mature protein coding sequence of clone vo28_l deposited with the ATCC under accession number PTA-1074.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo28_l deposited with the ATCC under accession number PTA-1074.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:54.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (ba) SEQ DD NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and (bb) the nucleotide sequence of the cDNA insert of clone vo28_l deposited with the ATCC under accession number PTA- 1074; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:53 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:53 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:53.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 3 to nucleotide 239, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 3 to nucleotide 239, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 3 to nucleotide 239.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 54 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:54.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.
  • such polynucleotide comprises the nucleotide sequence of SEQ DO NO:55 from nucleotide 49 to nucleotide 1452; the nucleotide sequence of SEQ ID NO:55 from nucleotide 109 to nucleotide 1452; the nucleotide sequence of the full-length protein coding sequence of clone vo29_l deposited with the ATCC under accession number PTA- 1074; or the nucleotide sequence of a mature protein coding sequence of clone vo29_l deposited with the ATCC under accession number PTA-1074.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo29_l deposited with the ATCC under accession number PTA- 1074.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 56 having biological activity, the fragment comprising the amino acid sequence from amino acid 229 to amino acid 238 of SEQ ID NO:56.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vo29_l deposited with the ATCC under accession number PTA- 1074; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO: 55 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO: 55 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:55.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 49 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:
  • nucleotide 109 to nucleotide 1452 from nucleotide 109 to nucleotide 1452, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 109 to nucleotide 1452, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 109 to nucleotide 1452.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 229 to amino acid 238 of SEQ ID NO:56.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:57.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:57 from nucleotide 48 to nucleotide 866; the nucleotide sequence of SEQ ID NO:57 from nucleotide 114 to nucleotide 866; the nucleotide sequence of the full-length protein coding sequence of clone vo30_l deposited with the ATCC under accession number PTA- 1074; or the nucleotide sequence of a mature protein coding sequence of clone vo30_l deposited with the ATCC under accession number PTA-1074.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vo30_l deposited with the ATCC under accession number PTA- 1074.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 131 to amino acid 140 of SEQ ID NO: 58.
  • step (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:57, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ DD NO:57 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:57 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:57.
  • the • polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 48 to nucleotide 866, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 48 to nucleotide 866, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 48 to nucleotide 866.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 114 to nucleotide 866, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 114 to nucleotide 866, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 114 to nucleotide 866.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:58 (b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and (c) the amino acid sequence encoded by the cDNA insert of clone vo30_l deposited with the ATCC under accession number PTA-1074; the protein being substantially free from other mammalian proteins.
  • the protein comprises the amino acid sequence of SEQ ID NO:58.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DO NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 131 to amino acid 140 of SEQ ID NO:58.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp25_l deposited with the ATCC under accession number PTA-1074;
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:59.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:59 from nucleotide 235 to nucleotide 510; the nucleotide sequence of SEQ ID NO:59 from nucleotide 316 to nucleotide 510; the nucleotide sequence of the full-length protein coding sequence of clone vp25_l deposited with the ATCC under accession number PTA- 1074; or the nucleotide sequence of a mature protein coding sequence of clone vp25_l deposited with the ATCC under accession number PTA-1074.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp25_l deposited with the ATCC under accession number PTA- 1074.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 41 to amino acid 50 of SEQ ID NO:60.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:59, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:59 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:59 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:59.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ DD NO:59 from nucleotide 235 to nucleotide 510, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO: 59 from nucleotide 235 to nucleotide 510, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 316 to nucleotide 510, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:59 from nucleotide 316 to nucleotide 510, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide 316 to nucleotide 510.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ DD NO:60, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 41 to amino acid 50 of SEQ ID NO:60.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:61.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 177 to nucleotide 1626; the nucleotide sequence of SEQ DO NO:61 from nucleotide 219 to nucleotide 1626; the nucleotide sequence of the full-length protein coding sequence of clone vq25_l deposited with the ATCC under accession number PTA- 1074; or the nucleotide sequence of a mature protein coding sequence of clone vq25_l deposited with the ATCC under accession number PTA-1074.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq25_l deposited with the ATCC under accession number PTA- 1074.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 62 having biological activity, the fragment comprising the amino acid sequence from amino acid 236 to amino acid 245 of SEQ ID NO:62.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from a nucleotide sequence conesponding to the 5' end of SEQ ID NO:61 to a nucleotide sequence conesponding to the 3' end of SEQ ID NO:61 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:61.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 61 from nucleotide 177 to nucleotide 1626, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ DD NO:61 from nucleotide 177 to nucleotide 1626, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 177 to nucleotide 1626.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence conesponding to the cDNA sequence of SEQ ID NO: 61 from nucleotide 219 to nucleotide 1626, and extending contiguously from a nucleotide sequence conesponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 219 to nucleotide 1626, to a nucleotide sequence conesponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 219 to nucleotide 1626.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 62 having biological activity, the fragment comprising the amino acid sequence from amino acid 236 to amino acid 245 of SEQ ID NO:62.
  • the polynucleotide is operably linked to an expression control sequence.
  • the invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) conesponding to the polynucleotide sequences disclosed herein.
  • Processes are also provided for producing a protein, which comprise:
  • the protein produced according to such methods is also provided by the present invention.
  • Protein compositions of the present invention may further comprise a pharmaceutically acceptable canier.
  • Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.
  • Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable canier.
  • Figures 1 A and IB are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.
  • nucleotide and amino acid sequences are reported below for each clone and protein disclosed in the present application.
  • the nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence.
  • the amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.
  • a "secreted” protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence.
  • "Secreted” proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed.
  • “Secreted” proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
  • vb24_l A polynucleotide of the present invention has been identified as clone "vb24_l".
  • vb24_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vb24_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vb24_l protein").
  • nucleotide sequence of vb24_l as presently determined is reported in SEQ ID NO: l, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb24_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ DD NO:2. Amino acids 3 to 15 of SEQ DD NO:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb24_l protein.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vb24_l should be approximately 6033 bp.
  • the nucleotide sequence disclosed herein for vb24_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FAST A search protocols.
  • vb24_l demonstrated at least some similarity with sequences identified as AB005299 (Homo sapiens BAI 3 mRNA, complete cds), AB011122 (Homo sapiens mRNA for KIAA0550 protein, complete cds), N50991 (yy94e07.sl Homo sapiens cDNA clone 281220 3'), and Q77404 (Human genome fragment (Prefened); standard; DNA).
  • the predicted amino acid sequence disclosed herein for vb24_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted vb24_l protein demonstrated at least some similarity to sequences identified as AB005299 (BAI 3 [Homo sapiens]) and W37412 (Human G-protein coupled receptor HD3CD07). Based upon sequence similarity, vb24_l proteins and each similar protein or peptide may share at least some activity.
  • the TopPredD computer program predicts eight potential transmembrane domains within the vb24_l protein sequence, centered around amino acids 16, 888, 923, 952, 993, 1030, 1100, and 1138 of SEQ ID NO:2, respectively.
  • the vb24_l protein shares significant amino acid sequence similarity with GenBank Accession Number AB005299 (BAI 3 [Homo sapiens]), which is a splice variant of GenBank Accession Number ABOl 1122 (KIAA0550 protein [Homo sapiens]), and shares amino acid similarity with other members of the B Al/secretin protein families.
  • the members of the B Al/secretin protein families are G-protein-coupled receptors.
  • the TopPredD profiles for some members of the BAI/secretin protein families are strikingly similar to that of vb24_l, with one transmembrane domain predicted at the N-terminus (approximately within the first 20 amino acids) and multiple transmembrane domains near the C-terminus.
  • the N-terminal transmembrane domains of the BAI/secretin protein family members are described as leader/signal sequences, consistent with the first transmembrane domain in the predicted vb24_l protein being a leader/signal sequence
  • vc64_l A polynucleotide of the present invention has been identified as clone "vc64_ l".
  • vc64_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vc64_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vc64_l protein”).
  • the nucleotide sequence of vc64_l as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail.
  • vc64_l demonstrated at least some similarity with sequences identified as AI217133 (qf47cl0.xl Soares_testis_NHT Homo sapiens cDNA clone IMAGE: 1753170 3', mRNA sequence), T19353 (Human gene signature HUMGS00377; standard; cDNA to mRNA), and Z49239 (A.thaliana mRNA for putative dTDP-glucose 4-6-dehydratases).
  • AI217133 qf47cl0.xl Soares_testis_NHT Homo sapiens cDNA clone IMAGE: 1753170 3', mRNA sequence
  • T19353 Human gene signature HUMGS00377; standard; cDNA to mRNA
  • Z49239 A.thaliana mRNA for putative dTDP-glucose 4-6-dehydratases.
  • the predicted amino acid sequence disclosed herein for vc64_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted vc64_l protein demonstrated at least some similarity to sequences identified as R98529 (dTDP-glucose dehydratase encoded by the acbB gene), U40800 (similar to thymidine diphosphoglucose 4,6-dehydratase [Caenorhabditis elegans]), and the dehydratases of many disparate species.
  • the hydratase protein family is very diverse with proteins ranging in length from less than 300 to more than 400 amino acids.
  • vc64_l protein appears to be an alternatively spliced variant of certain hydratases, and the existence of splice variants is also consistent with the diversity of the hydratase family. Based upon sequence similarity, vc64_l proteins and each similar protein or peptide may share at least some activity. vc64_l protein was expressed in a COS cell expression system, and an expressed protein band of approximately 5 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis. Clone "vp20 1"
  • vp20_l A polynucleotide of the present invention has been identified as clone "vp20_l”.
  • vp20_l was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vp20_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vp20_l protein").
  • nucleotide sequence of vp20_l as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp20_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.
  • Amino acids 34 to 46 of SEQ ID NO:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp20_ 1 protein.
  • vp20_l reading frame and predicted amino acid sequence is encoded by basepairs 910 to 1293 of SEQ ID NO:5 and is reported as SEQ ID NO:88.
  • Amino acids 9 to 21 of SEQ ID NO: 88 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of this predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO:88.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vp20_l should be approximately 1916 bp.
  • vp20_l The nucleotide sequence disclosed herein for vp20_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols.
  • vp20_l demonstrated at least some similarity with sequences identified as AA044732 (zk67e09.sl Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487912 3', mRNA sequence) and AA044769 (zk67e09.rl Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487912 5', mRNA sequence). Based upon sequence similarity, vp20_l proteins and each similar protein or peptide may share at least some activity.
  • the TopPredD computer program predicts two additional potential transmembrane domains within the vp20_l protein sequence, one centered around amino acid 60 and another around amino acid 87 of SEQ ID NO:6.
  • the TopPredD computer program also predicts one additional potential transmembrane domain within the protein of SEQ ID NO:88, centered around amino acid 80 of SEQ ID NO:88.
  • the nucleotide sequence of the vp20_l clone indicates that it may contain one or more MIR repeat sequences.
  • vq4_l A polynucleotide of the present invention has been identified as clone "vq4_ l".
  • vq4_l was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vq4_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vq4_l protein").
  • nucleotide sequence of vq4_l as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq4_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ DO NO:8.
  • Amino acids 7 to 19 of SEQ DD NO: 8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq4_l protein.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vq4_l should be approximately 831 bp.
  • nucleotide sequence disclosed herein for vq4_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and
  • vq4_l demonstrated at least some similarity with sequences identified as M75099. (Human rapamycin- and FK506-binding protein, complete cds), N36303 (yx99e09.rl Homo sapiens cDNA clone 2698965" similar to SW:FKB3_MOUSE P45878 FK506-BINDING PROTEIN PRECURSOR), and T 18037 (Human FKBP-13 immunophilin cDNA; standard; cDNA). The predicted amino acid sequence disclosed herein for vq4_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted vq4_l protein demonstrated at least some similarity to sequences identified as M75099 (rapamycin- and FK506-binding protein [Homo sapiens]) and R28980 (hRFKBP). Based upon sequence similarity, vq4_l proteins and each similar protein or peptide may share at least some activity.
  • the TopPredD computer program predicts two potential transmembrane domains within the vq4_l protein sequence, one centered around amino acid 14 and another around amino acid 164 of SEQ ID NO:8.
  • vo7_l A polynucleotide of the present invention has been identified as clone "vo7_l".
  • vo7_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vo7_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo7_l protein").
  • nucleotide sequence of vo7_l as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vo7_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ DD NO: 10.
  • Amino acids 14 to 26 of SEQ DD NO: 10 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo7_l protein.
  • nucleotide were added to the nucleotide sequence of SEQ ID NO: 9 between residue 477 and residue 484, and if a purine residue were added to the nucleotide sequence of SEQ ID NO:9 between residue 896 and residue 900, another potential vo7_l reading frame and predicted amino acid sequence encoded by what would then be basepairs 143 to 1336 of SEQ DD NO:9 is reported in SEQ ID NO:91.
  • Amino acids 14 to 26 of SEQ ID NO:91 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27.
  • the EcoRI Notl restriction fragment obtainable from the deposit containing clone vo7_l should be approximately 1740 bp.
  • vo7_l demonstrated at least some similarity with sequences identified as L04733 (Homo sapiens kinesin light chain mRNA, complete cds) and W07481 (za96d09.rl Soares fetal lung NbHL19W Homo sapiens cDNA clone 300401 5' similar to gb L04733 KINESIN LIGHT CHAIN (HUMAN); mRNA sequence).
  • the predicted amino acid sequence disclosed herein for vo7_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted vo7_l protein demonstrated at least some similarity to sequences identified as L04733 (kinesin light chain [Homo sapiens]). Movement of membrane-bounded organelles to intracellular destinations requires properly oriented microtubules and force-generating enzymes, such as the microtubule-stimulated ATPase kinesin. (See Cyr et al, 1991, Proc. Natl. Acad. Sci. USA 88(22): 10114-10118, which is incorporated by reference herein). Based upon sequence similarity, vo7_l proteins and each similar protein or peptide may share at least some activity.
  • vc65_l A polynucleotide of the present invention has been identified as clone "vc65_l”.
  • vc65_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vc65_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vc65_l protein").
  • the nucleotide sequence of vc65_l as presently determined is reported in SEQ ID NO:l 1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc65_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ DO NO: 12.
  • Amino acids 14 to 26 of SEQ DD NO: 12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc65_l protein.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vc65_l should be approximately 826 bp.
  • vc65_l The nucleotide sequence disclosed herein for vc65_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols.
  • vc65_l demonstrated at least some similarity with sequences identified as AA506313 (nh45c03.sl NCI_CGAP_Pr5 Homo sapiens cDNA clone IMAGE:955300 similar to TR:G685170 G685170 ADHERIN; mRNA sequence) and T22080 (Human gene signature HUMGS03624). Based upon sequence similarity, vc65_l proteins and each similar protein or peptide may share at least some activity.
  • vc66_l A polynucleotide of the present invention has been identified as clone "vc66_l".
  • vc66_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vc66_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vc66_l protein").
  • nucleotide sequence of vc66_l as presently determined is reported in SEQ ID NO: 13, and includes a poly (A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc66_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 14.
  • Amino acids 28 to 40 of SEQ ID NO: 14 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 41. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc66_l protein.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vc66_l should be approximately 1652 bp.
  • vc66_l The nucleotide sequence disclosed herein for vc66_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc66_l demonstrated at least some similarity with sequences identified as AA291293 (zsl ⁇ dl l.sl NCI_CGAP_GCB 1 Homo sapiens cDNA clone IMAGE 685557 3', mRNA sequence). Based upon sequence similarity, vc66_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vc66_l indicates that it may contain a LiMA5 repeat region.
  • vc68_l A polynucleotide of the present invention has been identified as clone "vc68_l".
  • vc68_l was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vc68_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vc68_l protein").
  • nucleotide sequence of vc68_l as presently determined is reported in SEQ ID NO: 15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc68_l protein conesponding to the foregoing nucleotide sequence is reported in SEQ ID NO: 16.
  • Amino acids 15 to 27 of SEQ DD NO: 16 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc68_l protein.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vc68_l should be approximately 2652 bp.
  • vc68_l demonstrated at least some similarity with sequences identified as AI147732 (qb47e06.xl NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE 1703266 3" similar to WP F55C5.2 CE11152
  • vc68_l proteins and each similar protein or peptide may share at least some activity.
  • the TopPred ⁇ computer program predicts an additional potential transmembrane domain within the vc68_l protein sequence centered around amino acid 38 of SEQ DD NO: 16.
  • the nucleotide sequence of vc68_l indicates that it may contain an Alu repetitive element.
  • vk6_l A polynucleotide of the present invention has been identified as clone "vk6_l".
  • vk6_l was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vk6_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vk6_l protein”).
  • the nucleotide sequence of vk6_l as presently determined is reported in SEQ ID
  • SEQ DD NO: 17 includes a poly(A) tail.
  • Amino acids 10 to 22 of SEQ DD NO: 18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vk6_l protein.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vk6_l should be approximately 4899 bp.
  • nucleotide sequence disclosed herein for vk6_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and
  • vk6_l demonstrated at least some similarity with sequences identified as AC006208 (Homo sapiens 3p21.1-9 PAC RPCI4-793P23 (Roswell Park Cancer Institute Human PAC Library) complete sequence), AH 27070 (qb97el0.xl Soares fetal heart NbHH19W Homo sapiens cDNA clone IMAGE 1708074 3', mRNA sequence), U28369 (Homo sapiens semaphorin V mRNA, complete cds), and V35367 (Human semaphorin encoding cDNA).
  • the predicted amino acid sequence disclosed herein for vk6_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted vk6_l protein demonstrated at least some similarity to sequences identified as U28369 (semaphorin V [Homo sapiens]) and W63748 (Human semaphorin).
  • the vk6_l amino acid sequence also demonstrated significant similarities to the semaphorin and collapsin proteins of many species. "The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules.” (Kolodkin et al., 1993, Cell 75(7): 1389-99, which is incorporated by reference herein).
  • vk6_l proteins and each similar protein or peptide may share at least some activity. Motif analysis detects an ATP/GTP-binding site motif A (P-loop) around residue 747 of SEQ ID NO: 18. The TopPredD computer program predicts two additional potential transmembrane domains within the vk6_ 1 protein sequence, one centered around amino acid 140 and another around amino acid 336 of SEQ ID NO: 18.
  • vo4_l A polynucleotide of the present invention has been identified as clone "vo4_ l".
  • vo4_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vo4_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo4_l protein”).
  • the nucleotide sequence of vo4_l as presently determined is reported in SEQ ID
  • SEQ DD NO:20 includes a poly(A) tail.
  • Amino acids 11 to 23 of SEQ DD NO:20 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo4_l protein.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo4_l should be approximately 2383 bp.
  • vo4_l The nucleotide sequence disclosed herein for vo4_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vo4_l demonstrated at least some similarity with sequences identified as AA613523 (nq22d01.sl NCI_CGAP_Col0 Homo sapiens cDNA clone IMAGE: 1144609, mRNA sequence), E12646 (cDNA encoding cell growth inhibiting factor), and Q60729 (Human brain Expressed Sequence Tag EST00852). The predicted amino acid sequence disclosed herein for vo4_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted vo4_l protein demonstrated at least some similarity to sequences identified as W74956 (Human secreted protein encoded by gene 77 clone HOEAS24) and Z92825 (C13C4.5 [Caeno-rhabditis elegans]). Based upon sequence similarity, vo4_l proteins and each similar protein or peptide may share at least some activity.
  • the TopPredD computer program predicts four additional potential transmembrane domains within the vo4_l protein sequence, centeres around amino acids 69, 114, 169, and 207 of SEQ DD NO:20, respectively.
  • vo8_l A polynucleotide of the present invention has been identified as clone "vo8_ l".
  • vo8_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vo8_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo8_l protein”).
  • the nucleotide sequence of vo8_l as presently determined is reported in SEQ ID
  • SEQ DD NO:22 amino acids 10 to 22 of SEQ DD NO:22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vo8_l protein.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone vo8_l should be approximately 3243 bp.
  • vo8_l proteins and each similar protein or peptide may share at least some activity.
  • vol0_l A polynucleotide of the present invention has been identified as clone "vol0_l".
  • vol0_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vol0_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vol0_l protein”).
  • the nucleotide sequence of vol0_l as presently determined is reported in SEQ ID NO:23, and includes a poly(A) tail.
  • volO_l The nucleotide sequence disclosed herein for volO_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols.
  • volO_l demonstrated at least some similarity with sequences identified as AI193090 (qe69e08.xl Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone IMAGE:1744262 3' similar to WP:F45G2.10 CE16053; mRNA sequence) and T 19307 (Human gene signature HUMGS00329).
  • the predicted amino acid sequence disclosed herein for vol0_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • vol0_l protein demonstrated at least some similarity to sequences identified as Z93382 (F45G2.10 [Caenorhabditis elegans]). Based upon sequence similarity, vol0_l proteins and each similar protein or peptide may share at least some activity.
  • a polynucleotide of the present invention has been identified as clone "vo20_l”.
  • vo20_l was isolated from a human adult pancreas cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • vo20_l is a full-length clone, including the entire coding sequence of a secreted protein (also refened to herein as "vo20_l protein").

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des protéines secrétées et des polynucléotides codant pour ces protéines, ainsi que l'utilisation de ces protéines et de ces polynucléotides à des fins thérapeutiques, diagnostiques et de recherche.
PCT/US2000/004340 1999-02-19 2000-02-18 Proteines secretees et polynucleotides les codant WO2000049134A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002362538A CA2362538A1 (fr) 1999-02-19 2000-02-18 Proteines secretees et polynucleotides les codant
AU28835/00A AU2883500A (en) 1999-02-19 2000-02-18 Secreted proteins and polynucleotides encoding them
JP2000599860A JP2002536973A (ja) 1999-02-19 2000-02-18 分泌タンパク質及びそれらをコードするポリヌクレオチド
EP00907313A EP1153121A2 (fr) 1999-02-19 2000-02-18 Proteines secretees et polynucleotides les codant

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US12068099P 1999-02-19 1999-02-19
US60/120,680 1999-02-19
US29873399A 1999-04-23 1999-04-23
US09/298,733 1999-04-23
US14963999P 1999-08-17 1999-08-17
US60/149,639 1999-08-17
US15568699P 1999-09-23 1999-09-23
US60/155,686 1999-09-23
US15724799P 1999-10-01 1999-10-01
US60/157,247 1999-10-01
US16782399P 1999-11-29 1999-11-29
US16782299P 1999-11-29 1999-11-29
US60/167,822 1999-11-29
US60/167,823 1999-11-29
US60/182,711 2000-02-15

Publications (2)

Publication Number Publication Date
WO2000049134A1 true WO2000049134A1 (fr) 2000-08-24
WO2000049134A8 WO2000049134A8 (fr) 2000-10-26

Family

ID=27568786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004340 WO2000049134A1 (fr) 1999-02-19 2000-02-18 Proteines secretees et polynucleotides les codant

Country Status (1)

Country Link
WO (1) WO2000049134A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070806A2 (fr) * 2000-03-20 2001-09-27 Lexicon Genetics Incorporated Nouvelles proteines humaines secretees et polynucleotides codant lesdites proteines
WO2002055985A3 (fr) * 2000-11-15 2003-07-10 Roche Diagnostics Corporation Methodes et reactifs permettant d'identifier des cellules embryonnaires rares dans le systeme circulatoire maternel
US7371842B2 (en) * 2002-04-26 2008-05-13 Astellas Pharma Inc. Polynucleotide encoding a 35 KDA protein thats binds to WF00144

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1132766A (ja) * 1997-05-23 1999-02-09 Otsuka Pharmaceut Co Ltd ヒトｂａｉ遺伝子及びその利用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1132766A (ja) * 1997-05-23 1999-02-09 Otsuka Pharmaceut Co Ltd ヒトｂａｉ遺伝子及びその利用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CYTOGEN. CELL. GENET.,, vol. 79, 1997, pages 103 - 108 *
CYTOGENET. CELL. GENET.,, vol. 79, no. 1-2, 1997, pages 103 - 108 *
DATABASE GENBANK NUCLEIC ACID, NCBI; SHIRATSUCHI ET AL.: "Cloning and characterization of BAI2 and BAI3, novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI 1)" *
DATABASE GENBANK PROTEIN, NCBI; SHIRATSUCHI ET AL.: "Cloning and characterization of BAI2 and BAI3, novel genes homologous to brain-specific angiogenesis inhibitors 1 (BAI 1)" *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070806A2 (fr) * 2000-03-20 2001-09-27 Lexicon Genetics Incorporated Nouvelles proteines humaines secretees et polynucleotides codant lesdites proteines
WO2001070806A3 (fr) * 2000-03-20 2002-04-11 Lexicon Genetics Inc Nouvelles proteines humaines secretees et polynucleotides codant lesdites proteines
US6815538B2 (en) 2000-03-20 2004-11-09 Lexicon Genetics Incorporated Human secreted proteins and polynucleotides encoding the same
WO2002055985A3 (fr) * 2000-11-15 2003-07-10 Roche Diagnostics Corporation Methodes et reactifs permettant d'identifier des cellules embryonnaires rares dans le systeme circulatoire maternel
US7371842B2 (en) * 2002-04-26 2008-05-13 Astellas Pharma Inc. Polynucleotide encoding a 35 KDA protein thats binds to WF00144

Also Published As

Publication number Publication date
WO2000049134A8 (fr) 2000-10-26

Similar Documents

Publication Publication Date Title
WO2000055375A1 (fr) Proteines secretees et polynucleotides les codant
EP1107978A1 (fr) Proteines secretees et polynucleotides codant pour ces proteines
US20050003491A1 (en) Secreted proteins and polynucleotides encoding them
WO1999042470A1 (fr) Proteines secretees et polynucleotides codant lesdites proteines
EP1068307A1 (fr) Proteines secretees et polynucleotides les codant
WO1999055721A1 (fr) Proteines secretees et polynucleotides les codant
WO1999041284A1 (fr) Proteines secretees et polynucleotides les codant
WO2000050592A1 (fr) Proteines secretees et polynucleotides les codant
WO1999046287A1 (fr) Proteines secretees et polynucleotides les codant
EP1040118A1 (fr) Proteines secretees et polynucleotides les codant
WO2000049134A1 (fr) Proteines secretees et polynucleotides les codant
WO1999053045A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
WO1999035252A2 (fr) Proteines secretees et polynucleotides les codant
WO1999026973A1 (fr) Proteines secretees et polynucleotides les codant
EP1017719A1 (fr) Proteines secretees et polynucleotides les codant
EP1153121A2 (fr) Proteines secretees et polynucleotides les codant
EP1049714A1 (fr) Proteines secretees et polynucleotides les codant
EP1064302A1 (fr) Proteines secretees et polynucleotides les codant
EP1053306A1 (fr) Proteines secretees et polynucleotides les codant
EP1268834A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
WO1999051732A1 (fr) Proteines secretees et polynucleotides codant pour ces proteines
WO1999035165A1 (fr) Proteines secretees et polynucleotides les codant
EP1037970A1 (fr) Proteines secretees et polynucleotides les codant
EP1028974A1 (fr) Proteines secretees et polynucleotides les codant
EP1012263A1 (fr) Proteines secretees et polynucleotides les codant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2362538

Country of ref document: CA

Ref country code: CA

Ref document number: 2362538

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 599860

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000907313

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000907313

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000907313

Country of ref document: EP